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Summary In this study we have screened a series of 29 primary leiomyosarcomas for abnormalities of both
the p53 gene and the MDM2 gene, which encodes a p53-associated protein. SSCP (single-strand conformation
polymorphism) analysis and direct sequencing of polymerase chain reaction (PCR)-amplified DNA were used
to establish that 6/29 tumours possessed point mutations of the p53 gene. Using a monoclonal antibody that
recognises the p53 protein in immunohistochemical staining experiments, we observed overexpression of the
p53 protein in five of the six tumours containing point mutations in the p53 gene. Southern analysis of tumour
DNA revealed that 2/29 tumours demonstrated amplification of the MDM2 gene. When considered together,
these results indicate that alterations in both the p53 gene and MDM2 gene are important in the development
of a significant minority of leiomyosarcomas. In addition, we have demonstrated a significant association
between the presence of abnormalities of the p53 gene or MDM2 genes in leiomyosarcomas and a more
advanced clinicopathological stage (P = 0.03). We have also examined the role of the DCC tumour-suppressor
gene in the development of human soft-tissue tumours in a variety of histological types. Except for evidence of
a rearrangement in a single leiomyosarcoma cell line, SK-UT-1, we have found no direct evidence to support a
role for mutation of the gene in the development of human soft-tissue tumours.
Mutations of the p53 tumour-suppressor gene are the most
common genetic alteration observed in human tumours in-
cluding the common adult epithelial malignancies of breast
(Prosser et al., 1990), colon (Baker et al., 1989) and lung
(Takahashi et al., 1989). Originally identified through its
association with SV40 large T antigen in virus-transformed
cells (Lane & Crawford, 1979) and as an overexpressed
antigen in chemically transformed sarcoma cells (DeLeo et
al., 1979), p53 was initially classified as an oncogene because
of its ability to transform cells in culture (Eliyahu et al.,
1984; Jenkins et al., 1984). Subsequent analysis associated
this property with a mutant p53 clone (Hinds et al., 1989),
and evidence of deletion of both alleles of the gene in eryth-
roleukaemia cell lines (Mowat et al., 1985), loss of
heterozygosity at the p53 locus in a variety of tumours and
evidence of a tumour-suppressive function for wild-type p53
(Chen et al., 1990) established p53 as a tumour-suppressor
gene.
The majority of p53 mutations are missense point muta-
tions (Hollstein et al., 1991; Levine et al., 1991) clustered in
the most highly conserved domains of the gene spanned by
exons 4-9 (Soussi et al., 1990). Missense mutations fre-
queritly induce changes that prolong the half-life of the p53
protein (Finlay et al., 1988), and as a result mutant p53,
unlike wild-type p53, accumulates in tumour cells to levels
detectable by immunohistochemical methods. Elevated levels
of p53 have been detected immunohistochemically in several
tumour types, and when p53 has been sequenced in these
tumours missense mutations are usually found (Bartek et al.,
1990; Rodrigues et al., 1990).
The MDM2 gene, which encodes a p53-associated protein,
was first identified as a dominantly transforming oncogene in
a tumorigenic mouse fibroblast cell line containing double-
minute chromosomes, the cytogenic hallmark of gene
amplification (Fakharzadeh et al., 1991). Following this, the
rat homologue of the MDM2 gene was subsequently found
to form a complex with the p53 gene, to inhibit p53-mediated
transactivation (Momand et al., 1992), and amplification of
Correspondence: H. Patterson, Section of Molecular Carcinogenesis,
Institute of Cancer Research, 15 Cotswold Road, Belmont, Sutton,
Surrey SM2 5NG, UK.
Received 6 August 1993; and in revised form 8 February 1994.
the MDM2 gene has been observed in liposarcomas, malig-
nant fibrous histiocytomas and osteosarcomas (Oliner et al.,
1992).
A candidate suppressor gene, DCC (deleted in colorectal
carcinoma), has recently been cloned by mapping a region of
chromosome 18q that frequently shows allelic deletion in
sporadic colorectal carcinomas (Fearon et al., 1990). In keep-
ing with the idea that DCC is a suppressor gene, injection of
anti-sense RNA to the DCC gene results in the transforma-
tion of Rat-I fibroblasts (Narayanan et al., 1992).
We have previously described mutations of the p53 and
RBI tumour-suppressor genes in human sarcomas (Stratton
et al., 1989, 1990). Abnormalities of the p53 gene were most
frequently found in leiomyosarcomas and rhabdomyosar-
comas, but only a limited series of primary leiomyosarcomas
were examined and only a single exon, exon 5, of the p53
gene was screened for point mutations in these tumours. We
have extended these studies by systematically screening a
series of primary leiomyosarcomas for abnormalities of p53
using (i) immunohistochemical staining to screen for p53
overexpression, (ii) SSCP analysis to screen for point muta-
tions in exons 4-9 of the p53 gene and (iii) direct sequencing
analysis to define point mutations. In addition, we have also
used Southern analysis to screen leiomyosarcomas for
amplification of the MDM2 gene. We subsequently used
these data to determine if there was any association between
abnormalities of the p53 and MDM2 genes and patient
survival or established prognostic indicators such as
clinicopathological stage and histological grade for
leiomyosarcomas.
We have also examined the expression and evaluated the
evidence for mutation or deletion of the DCC gene in a large
series of sarcoma cell lines and primary soft-tissue tumours
of all histological types.
Materials and methods
Clinical samples and cell lines
Fresh specimens of primary soft-tissue sarcomas were
obtained during surgical resection from the Royal Marsden
Hospital, London and Surrey, St Thomas's Hospital, London,
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and the Royal Orthopaedic Hospital, Birmingham. Samples
were immediately snap frozen in liquid nitrogen and stored at
-70°C until processed. Tumours were additionally fixed in
formalin or methacarn and embedded in paraffin. Non-
neoplastic tissues from sarcoma patients were obtained in the
form of peripheral blood lymphocytes, skeletal muscle or
dermal fibroblasts. Cell lines with the exception of RMS
(Garvin et al., 1986) and MNNG-HOS (Rhim et al., 1975)
were obtained from the American Type Culture Collection
(ATCC) and maintained as recommended by their supplier.
Patient data
Samples of leiomyosarcomas were available from 29 patients,
20 males and nine females, who underwent surgical resection
between August 1980 and March 1991. Five patients under-
went initial surgical resection at other hospitals and were
referred to the Royal Marsden Hospital for further manage-
ment. The mean age was 54 years (26-79 years). Follow-up
data were available for all patients, with a median follow-up
of 25 months. All patients were managed primarily with
surgical resection and where appropriate received adjuvant
radical radiotherapy. Isolated hepatic and pulmonary meta-
stases were managed where possible by surgical resection.
Thirteen patients received chemotherapy, for metastatic or
residual disease, with adriamycin 40-60 mg-2, ifosfamide
5gm2 and mesna. Six patients demonstrated an objective
response to chemotherapy and seven patients had progressive
disease.
Southern analysis
DNA was extracted from tumours and normal tissue by
published protocols (Steffen & Weinberg, 1978). DNA was
digested with a 3- to 5-fold excess of an appropriate restric-
tion enzyme, subjected to electrophoresis in 0.8% agarose
gels and transferred to Hybond-N filters (Amersham) accord-
ing to the manufacturer's instructions. Filters were hybridised
according to published protocols (Church & Gilbert, 1984) to
x-32P-labelled probes prepared using random oligonucleotide
primers (Feinberg & Vogelstein, 1983).
Rearrangement of the DCC gene was analysed using two
partial cDNA probes, pDCC1.0 and pDCC1.65 (Fearon et
al., 1990). Amplification of the MDM2 gene was assessed
using a 1.5 kb MDM2 probe prepared by PCR amplification
of reverse-transcribed normal fibroblast RNA using the fol-
lowing primers: GGGAGCTCCTCGCCACCATGGTGAG-
GAGCAGGCAAATG and GGGGTACCCTCATAGACA-
GGTCAACTAGGGG. The PCR product was subcloned
into the pBluescript vector and characterised by sequencing
of its entire length. Following hybridisation to the MDM2
probe, blots were stripped by immersion in 0.1% sodium
dodecyl sulphate (SDS) at 95°C and reprobed with pDCCI.0
as a control to correct for differences between tumour sam-
ples in DNA loading and Southern transfer (Oliner et al.,
1992). The degree of amplification was quantified with a
Joyce Loebel Chromoscan 3 scanning densitometer, using
absorbance at 530 nm.
Evidence for DNA insertion within a 0.17 kb XbaI-
EcoO109 fragment of the DCC gene (Fearon et al., 1990) was
examined by probing Southern blots of EcoRI-EcoOI09-
digested DNA of peripheral blood and tumour pairs with a
probe that detects a single 600 bp EcoRI-EcoO109 fragment
that spans the 0.17 kb XbaI-EcoO109 fragment. The probe
was made by PCR amplification of normal DNA using the
following primers: GGAGGAAGCAACTTACGGAT and
TCTAGAGGGAAAATGTCATC.
Loss of heterozygosity on chromosome 18q was assessed
using the following probes: pERT25 (D18Sl1), which detects
a VNTR at 18q23, and OLVIIEIO (D18S8) (Marlhens et al.,
1987), SAM1.1 and JOSH4.4, which are polymorphic probes
from within the DCC gene. pERT25 was obtained from the
ATCC.
PCR amplification
The p53 and DCC genes were amplified from extracted cel-
lular DNA by 30 cycles of the polymerase chain reaction
(Saiki et al., 1988) with 1 min at 92°C, 1 min at 57°C and
1 min at 72°C in a 50;lI reaction containing 200 ng of
genomic DNA, 60 mM potassium chloride, 15 mM Tris-HCl
pH 8.8, 2.25 mM magnesium chloride, 25 pmol of each
primer, 200fLM of each dNTP and 1 unit of Taq polymerase
(Bethesda Research Laboratories). For sequence analysis one
primer of each pair was biotin labelled. For SSCP analysis
one primer was end labelled with 0.3 pmol of [7y-32P]ATP
(specific activity 6,000 Ci mmol 1) prior to the PCR reaction,
or 0.6 pmol of [_-32P]dCTP (specific activity 3,000 Ci mmol- )
was added to each sample prior to amplification.
PCR primers for analysis of the p53 gene were as follows:
lows:
Exon 4 GACCTGGTCCTCTGACTGCT and
GCATTGAAGTCTCATGGAAG
Exon S ATCTGTTCACTTGTGCCCTG and
ATCAGTGAGGAATCAGAGGC
Exon 6 GCCTCTGATTCCTCACTGAT and
GGAGGGCCACTGACAACCA
Exon 7 CTTGCCACAGGTCTCCCCAA and
AGGGGTCAGCGGCAAGCAGA
Exon 8 TTCCTTACTGCCTCTTGCTT and
TGAATCTGAGGCATAACTGC
Exon 9 GCAGTTATGCCTCAGATTCA and
ACTTTCCACTTGATAAGAGG.
SSCP analysis
A 2ftl aliquot of each PCR product was mixed with 8jil
loading buffer (95% formamide, 20 mM EDTA, 0.05%
bromophenol blue and 0.05% xylene cyanol EF) heated to
85°C for 2 min, and 3 gd of this mixture loaded onto 6%
(w/v) polyacrylamide gels (19:1, acrylamide-bisacrylamide)
containing 0.5 x TBE (45mM Tris-borate, pH 8.3, 1 mM
EDTA) or 1 x TBE (90 mM Tris-borate, pH 8.3, 2 mM
EDTA). Electrophoresis was performed at 40W for 3 h at
4°C. After drying, the gel was exposed to radiographic film
for 12 h to 7 days. A combination of 6% gels and 0.5 x TBE
gave the best resolution of mutant bands in exons 4, 5 and 7.
A combination of 6% acrylamide and 1 x TBE showed exon
8 mutations most clearly.
Direct sequencing
Following PCR amplification, samples were purified using
streptavidin-coated magnetic beads (Dynal, UK) and
sequenced as previously described (Gusterson et al., 1991),
using [a35S]dATP and Sequenase Version 2.0 (United States
Biochemicals).
Analysis ofgene expression using PCR
RNA was extracted from subconfluent cultures of cell lines
and normal human fibroblasts as previously described
(Favaloro et al., 1980). A 0.2ytg aliquot of total RNA was
reverse transcribed with random hexamer primers (Noonan
& Roninson, 1988) and the resulting cDNA amplified by
PCR as described above. The PCR product was run in 2%
(w/v) agarose gels, blotted and hybridised at 55°C to 30-mer
oligonucleotide probes complementary to sequences internal
to the corresponding primers, and end labelled with
['y-32P]ATP. Filters were washed in 2 x SSC, 0.1% SDS, at
55°C and exposed to radiographic film for 30min to 12h.
The primers were as follows:
DCC
Internal probe
AGCCTCATTTTCAGCCACACA
and TTCCGCCATGGTTTTTAAAT-
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AATGGAGATGTGGTCATTCCTA-
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Table I Immunohistochemical and mutational analyses of the p53 gene in human leiomyosarcomas
Immunohistochemistry SSCP
with p53-DO7 analysis pS3 sequencing analysis
SSCP
Case Paraffin Frozen abnormality Exon Codon Mutation Amino acid change
STS16 - + + + 5 151 CCC-*CAC Pro+His
STS28 + + + ND + 7 238 TGT+TTT Cys-*Phe
STS38 - - + 7 - Wild typeb
STS65 - - ND - - Homozygous deletion
STS90 - + + + + 8 272 GTG-*ATG Val+Met
STS129 + + + + - 5 158 CGC+CAC Arg+His
STS158 - - ND - - Homozygous deletion
STS184 - - + 5 152 CCG-*CTG Pro-Leu
STS328 + + + + - 6 216 GTG+ATG Val-*Met
20 others - - - - - Wild type
aThe degree of immunohistochemical staining was graded as follows: (+), < 10% nuclei staining; (+ +), 10-50% nuclei
staining; (+ + +), >50% nuclei staining; and (-), negative results. bSequencing of exon 7 in STS38 showed normal exonic
sequence and splice junctions. SSCP had detected a sequence variation in intron 6. Thirty-four nucleotides upstream of exon
7 the sequence GCGCA becomes GCCCA. ND, analysis not performed.
P2-Microglobulin ACCCCCACTGAAAAAGATGA
and ATCTTCAAACCTCCATGATG
Internal probe GAACCACGTGACTTTGTCACAG-
CCCAAGAT.
Immunohistochemistry
The mouse monoclonal antibody p53-DO7, which recognises
both mutant and wild-type human p53, was used to stain
both frozen and paraffin-embedded tumour material using a
standard peroxidase-conjugated streptavidin-biotin method
(ABC). Control slides omitting the first antibody were
negative in all cases. The degree of immunostaining was
graded as follows: (+), <10% nuclei staining intensely;
(+ +), 10-50% nuclei staining intensely; (+++ +), >50%
nuclei staining intensely.
Statistical analyses
Differences in overall survival and disease-free survival
between patients with or without p53/MDM2 mutant
tumours were tested using log-rank tests and were plotted
according to the Kaplan-Meier method. The association
between p53/MDM2 mutation and clinical variables such as
age, tumour site, American Joint Committee (AJC) clinical
stage (Russell et al., 1977) and histological grade were
assessed using appropriate chi-square tests. The date of the
definitive operative procedure was taken as the date of diag-
nosis.
Results
Overexpression ofp53 in leiomyosarcomas
Using the monoclonal antibody p53-DO7, immunostaining
demonstrated overexpression of the p53 protein in five
tumours (Table I, Figure 1).
Abnormalities ofthep53 gene detected by SSCP analysis and
DNA sequencing
SSCP was used to screen 29 leiomyosarcomas for point
mutations in exons 4-9 of the p53 gene. SSCP analysis can
detect point mutations in PCR-amplified segments of DNA
by virtue of the fact that the rate at which PCR-amplified
segments of single-stranded DNA migrate in non-denaturing
gels depends upon both the strand size and base composition
of the PCR product (Orita et al., 1989). Abnormal SSCP
band patterns were detected in five tumours (Table I, Figure
2), and three of these tumours had demonstrated p53 over-
expression in immunostaining experiments.
Direct sequencing of the PCR products that gave abnor-
mal SSCP patterns and each of the exons 4-9 in the two
a
b
Figure 1 Immunostain analysis of p53 expression in primary
leiomyosarcomas. a, Positive nuclear staining of a frozen section
of STS90. The majority of the nuclei stain intensely. b, Immuno-
staining of a frozen section of STS90 omitting the monoclonal
antibody p53-DO7. The scale bar represents 50prm.
tumours which stained positively for the p53 protein but
failed to show SSCP abnormalities revealed that in each case
the DNA sequence contained a point mutation. Examples are
shown in Figure 3. Six tumours possessed missense point
mutations, however in STS 38 the mutation causing the
SSCP abnormality occurred in intron 6, 34 bp upstream ofTUMOUR-SUPPRESSOR GENE MUTATION IN LEIOMYOSARCOMAS 1055
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Figure 2 PCR-SSCP analysis of p53 mutations in primary leiomyosarcomas. Non-denatured samples are designated D, and
normal samples N. P is a positive control sample containing a mutation in exon 8. The results show (a) SSCP abnormalities of
exon 5 in tumours STSl6 and STS184, (b) SSCP abnormalities of exon 7 in STS28 and STS38 and (c) SSCP abnormality of exon 8
in STS90.
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Figure 3 p53 sequence analysis of primary leiomyosarcomas.
These results show (a) a TGT-*TTT transversion coding for the
amino acid change Cys-*Phe in codon 238 (exon 7) in STS28
and (b) a GTG-*ATG transition coding for the amino acid
change Val-*Met in codon 272 (exon 8) in STS90.
DCC
Figure 4 Amplification of the MDM2 gene in STS87 and
STS320. The degree of amplification seen in STS87 is maintained
in each of three subsequent recurrences designated 87A, 87B,
87C. N, Normal lymphocyte DNA. The Southern blot was
exposed for 96 h at - 70°C following hybridisation to pDCC1.0,
and for 16h following hybridisation to the MDM2 probe, to
avoid overexposure of the amplified samples.
exon 7. In addition, we have previously shown that two of
the tumours in this study group had undergone homozygous
deletion of the p53 gene (Stratton et al., 1990). Taken
together, these results show that 8/29 (28%) of the
leiomyosarcomas in our study group possessed missense
point mutations or had undergone deletion of the p53 gene.
These results are summarised in Table I.
Amplification ofthe MDM2 gene
Tumours which demonstrated in excess of a 5-fold increase in
the signal with the MDM2 probe relative to the signal seen
with pDCCL.0 were considered to show MDM2 amplifi-
cation. pDCC1.0 was considered a reasonable control probe
as hemizygous loss of chromosome 18q, the DCC locus, as
reported in this paper, occurs in only 10% of sarcomas, a
level consistent with the background loss observed with most
genetic markers. Southern analysis demonstrated amplifi-
cation of the MDM2 gene in 2/29 leiomyosarcomas. STS 87,
a metastasis from a primary tumour, showed a 60-fold
amplification in the MDM2 gene. The amplification was
maintained at a similar level in each of three subsequent
recurrences. A 120-fold amplification of the MDM2 gene was
seen in STS 320, a locally advanced primary tumour (Figure
4). Although densitometry may be unable to measure amplifi-
cation of this degree accurately, the levels of MDM2
amplification in these tumours are clearly significant.
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Table II Association between clinical features and the presence of p53 and MDM2 mutations in leiomyosarcomas
p53 status p53 + MDM2 status
Clinical feature Normal Mutant Total P-value Normal Mutant Total P-value
Clinicopathological stagea
IA/Bb 1 0 1 1 0 1
IIA/B 6 1 7 0.08c 6 1 7 0.03c
IIIA/B 8 2 10 7 3 10
IVA/B 3 4 7 2 5 7
Pathological grade
lb 2 1 3 1 2 3
II 8 2 10 0.67 8 2 10 0.42
III 11 5 16 10 6 16
Tumour site
Abdominald 11 3 14 10 4 14
Limb 7 4 11 0.58 6 5 11 0.56
Bladder 2 0 2 2 0 2
Uterine 1 1 2 1 1 2
Patient age (years)
<58 12 3 15 0.43 11 4 15 0.45
> 58 9 5 14 8 6 14
aAmerican Joint Committee staging system. bowing to their small numbers stage I and grade I tumours were excluded from these
statistical analyses. cP-value calculated from test for trend method. dIncludes retroperitoneal and mesenteric tumours.
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Figure 5 Kaplan-Meier actuarial survival curves for
leiomyosarcoma patients in this study. a, Overall survival by
clinicopathological stage. b, Overall survival by p53 mutation. c,
Overall survival by p53 and MDM2 mutation.
Correlation ofp53/MDM2 mutations with clinical data
Of the 29 primary leiomyosarcomas analysed in this study,
25 arose in soft tissue, two arose in the bladder and two were
uterine in origin. Analyses correlating AJC clinical staging
and p53/MDM2 mutation were restricted to tumours arising
in the retroperitoneum, the mesentery and the limb. Rare
tumours arising in the uterus and bladder were omitted from
this analysis. STS38 (which possesses an intronic mutation)
was considered to possess wild-type p53 for the purposes of
the molecular and clinical correlation analyses.
p53 mutation alone was not significantly associated with
patient age, site of primary tumour, tumour stage, overall
survival or disease-free survival. There was, however, some
evidence that p53 mutation alone was associated with a more
advanced tumour stage (P = 0.08). When p53 mutations and
MDM2 amplification were considered together, the presence
of either a p53 mutation or amplification of the MDM2 gene
was significantly associated with advanced tumour stage
(P = 0.03). The survival curves for patients with mutant (p53
or MDM2) and non-mutant tumours were not significantly
different. The results are summarised in Table II and Figure
5.
Abnormalities ofthe DCC gene
A number of approaches have been used to screen a variety
of sarcomas, including liposarcomas, malignant fibrous
histiocytomas, leiomyosarcomas, malignant peripheral nerve
sheath tumours, rhabdomyosarcomas, synovial sarcomas and
fibrosarcomas, for abnormalities in the DCC gene. Analysis
of DCC expression by PCR amplification of cDNA revealed
DCC expression in only two of the eight sarcoma cell lines
examined, HT1080 and A673 (Figure 6a).
Southern analysis of 78 primary sarcomas and 12 sarcoma
cell lines, using the probes pDCCl.0 and pDCCI.6, identified
a single cell line, SK-UT-1, with an abnormal band pattern
in both HindIII- and EcoRI-digested DNA (results not
shown). Of 12 mutations originally observed in the DCC
gene, ten involved DNA insertion within a 600 bp EcoRI-
EcoOl09 fragment of the gene. This DNA insertion has
proved to be unclonable (Fearon et al., 1990). Southern
analysis of EcoRI-EcoOI09 double-digested SK-UT-1 DNA
suggests that the abnormal band pattern seen in this cell
represents such an insertion mutation (Figure 6b).
Finally, analysis of loss of heterozygosity on 18q revealed
an allelic loss rate in sarcomas ofonly 10% (3/29 informative
blood-tumour pairs).
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Figure 6 Analysis of the DCC gene. a, RNA-PCR analysis of DCC expression in eight sarcoma cell lines. Total RNA was reverse
transcribed and the resulting cDNA amplified by PCR. The product was run in 2% gels, blotted and probed with radiolabelled
oligonucleotide probes internal to the corresponding primers. The cell lines examined were as follows: (a) SK-UT-1, a leiomyosar-
coma; (b) Hs913T and (c) HT1080, both fibrosarcomas; (d) RMS, (e) RD, (f) A204 and (g) A673, all rhabdomyosarcomas; (h)
MNNG-HOS, a chemically transformed sarcoma cell line. The expected 233 bp PCR product was amplified from two of the cell
lines, HT1080 and A673. A band corresponding to PCR amplification of DNA (D) was not seen, and DCC expression in normal
human fibroblasts was not detected by this method (results not shown). Detection of ubiquitously expressed P2-microglobulin was
used as a positive control for these experiments. The expected 103 bp band was amplified from all cell lines. In the control lanes (C)
reverse-transcribed RNA was omitted from the PCR reaction. b, Evidence for an insertion mutation of the DCC gene in the cell
line SK-UT-1. Genomic DNA from the cell line SK-UT-1 (T) was digested with EcoRI and EcoO109 separated in 0.8% agarose
gels, blotted and hybridised to a radiolabelled 290 bp PCR probe from within the DCC gene. A novel band pattern, not found in
any of the other 89 sarcoma samples analysed, was detected and appears to represent a DNA insertion mutation in the DCC gene.
The band pattern attained with normal DNA (N) is shown for comparison.
Discussion
Taken together, the Southern, immunohistochemical, SSCP
and sequencing analyses show that 28% (8/29) of our series
of primary leiomyosarcomas possess mutations of the p53
gene. Mutations were found in soft-tissue tumours arising in
the limb and abdomen and in a single uterine tumour. This
mutation rate is lower than that generally found by similar
analyses in several common epithelial tumour types (Baker et
al., 1989; Takahashi et al., 1991). Using the same primers,
SSCP analysis detected 90% (18/20) of p53 point mutations
in a number of exons (Condie et al., 1993). We believe
therefore, that the combination of Southern analysis, SSCP
analysis and immunostaining provides a powerful approach
with which to detect the majority of p53 mutations.
Immunostaining was positive in 5/6 tumours found to pos-
sess p53 point mutations. The false-negative result observed
with immunostaining of both fixed and frozen tumour
material of STS184 may reflect the fact that this mutation
does not sufficiently stabilise the mutant p53 protein for its
detection by this method. In addition, a single tumour
demonstrating a novel intronic allele was immunostain
negative. Unfortunately, we were unable to analyse germ-line
DNA or tumour-specific RNA from this patient, and in view
of this the possibility remains that this sequence variation,
not seen in any of the other tumours or normal specimens
examined by SSCP, represents an intronic mutation pertinent
to tumour development rather than simply an intronic
polymorphism.
Our study provides the first examples of amplification of
the MDM2 gene in leiomyosarcomas. Experimental evidence
suggests that amplification of the MDM2 gene may provide
an alternative mechanism by which the action of the p53
gene is blocked in tumour cells. In keeping with this, neither
of the tumours that demonstrated MDM2 amplification pos-
sessed a mutation in the p53 gene. Taken together these
results suggest the function of the p53 gene may be disrupted
in 34% (10/29) of our leiomyosarcomas.
Following our systematic analysis of p53 and MDM2
mutations in a single histological category of sarcoma we
proceeded to correlate our molecular data with known
clinical prognostic variables. p53 mutations were observed in
all grades of tumour and a statistically significant association
between a more advanced tumour stage and the presence of a
p53 mutation or MDM2 amplification was observed
(P = 0.03). The role of p53 mutations in the multistage pro-
cess of sarcoma development is not yet defined, although we
have already demonstrated that in some sarcomas the coinci-
dent loss of both the RBI and the p53 tumour-suppressor
genes appears important for the development of the fully
malignant phenotype (Stratton et al., 1990). The association
between p53/MDM2 mutation and advanced clinicopatho-
logical stage suggests that p53 mutation may be a late event
in sarcoma development, as observed in colorectal tumori-
genesis (Baker et al., 1990). Recently, several studies have
emerged correlating the presence of p53 mutations with ag-
gressive tumour phenotypes (Martin et al., 1992; Visakorpi et
al., 1992) and, most notably, a recently published study by
Allred et al. (1993) has shown that p53 mutation, demon-
strated by immunohistochemical positivity, is an independent
prognostic indicator in multivariate analyses for node-
negative breast cancer.
Leiomyosarcomas of deep soft tissue generally have a very
poor prognosis, and this may explain why in our study
neither histological grade, clinical stage nor p53/MDM2
mutation predicted overall survival or disease-free survival. A
similar study involving a larger group of patients may help
resolve whether p53/MDM2 mutation will also predict prog-
nosis in patients with this type of tumour.
Examination of 90 sarcomas showed evidence of mutation
of the DCC gene in only a single leiomyosarcoma cell line,
SK-UT-1, in which DCC expression as assessed by RNA-
PCR analysis was absent. Only 10% of the sarcomas
examined showed loss of heterozygosity at the DCC locus,
comparing unfavourably with LOH rates of 36% and 23% at
the p53 and RBJ loci respectively (Stratton et al., 1990;
1989), both of which we believe are important in sarcoma
development. These results argue against a significant role for
mutation of the DCC gene in sarcoma development.
The probes pDCCl.0, pDCCl.65, JOSH4.4 and SAM1.l were a kind
gift from Professor Bert Vogelstein. The polymorphic probe
OLVIIEIO was kindly donated by Dr Gilles Thomas, and the
MDM2 probe by Dr Alasdair Stamps. The p53 monoclonal antibody
was a gift from Dr David Lane. We would like to thank Deborah
Eagle for help in collating the clinical data. This work is supported
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